Background: The performance and parasitology of semi-intensively managed West African dwarf (WAD) lambs were evaluated following exposure to gastrointestinal helminth infected paddock and varied protein-energy feeds.

Methods: Twenty four lambs obtained from the Department of Animal Breeding and Genetics and brought to Directorate of University farm (DUFARM) of Federal University of Agriculture Abeokuta, Ogun state, Nigeria, where the research was carried out in 2014, were grouped into four each containing six animals based on different energy-protein feed combination thus; group 1(G1) low energy low protein, group 2 (G2) low energy high protein, group 3 (G3) high energy low protein and group 4 (G4) high energy high protein. Experimental animals were supplemented with concentrate feed after grazing on daily in a nematode infected paddock. Clinical signs of infection were monitored. Live weight, faecal egg count (FEC), worm counts, packed cell volume (PCV), haemoglobin concentration (Hb) and red blood cell count (RBC) were determined using standard methods.

Results: Anorexia and intermittent diarrhea were the observed signs. Worm counts did not differ significantly (=0.309) among the groups. The weight and FEC differed significantly (<0.05) across the days and among the groups, while haematological parameters increased significantly (<0.05) across the days and among the groups.

Conclusion: Lambs in G2 followed by G4 showed improved parameters and superior performance when compared to the other groups. It is therefore recommended that feed high in protein content is capable of mitigating deleterious effect of gastrointestinal helminth parasitism.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5251185PMC

Publication Analysis

Top Keywords

protein group
12
performance parasitology
8
parasitology semi-intensively
8
semi-intensively managed
8
managed west
8
west african
8
african dwarf
8
gastrointestinal helminth
8
helminth infected
8
varied protein-energy
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, U.S.A., Philadelphia, PA, USA.

Background: The vicious cycle between depression and dementia increases the risk of Alzheimer's Disease (AD) pathogenesis and pathology. This study investigates therapeutic effectiveness versus side effects and the underlying mechanisms of intranasal dantrolene nanoparticles (IDNs) to treat depression behavior and memory loss in 5XFAD mice.

Method: 5XFAD and wild-type B6SJLF1/J mice were treated with IDNs (IDN, 5 mg/kg) in Ryanodex formulation for a duration of 12 weeks.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

NYU Grossman School of Medicine, New York, NY, USA; NYU, New York City, NY, USA.

Background: Astrocytes, a major glial cell in the central nervous system (CNS), can become reactive in response to inflammation or injury, and release toxic factors that kill specific subtypes of neurons. Over the past several decades, many groups report that reactive astrocytes are present in the brains of patients with Alzheimer's disease, as well as several other neurodegenerative diseases. In addition, reactive astrocyte sub-types most associated with these diseases are now reported to be present during CNS cancers of several types.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Alnylam Pharmaceuticals, Cambridge, MA, USA.

Background: The hyperphosphorylation, mislocalization, and aggregation of the microtubule associated protein Tau (MAPT) is a driving force in tauopathies, a group of progressive, neurodegenerative disorders. These pathogenic intracellular aggregates, known as neurofibrillary tangles (NFTs), are a hallmark in several diseases such as frontotemporal dementia, progressive supranuclear palsy, and Alzheimer's Disease. While anti-Tau immunotherapies emphasize the clearance of extracellular Tau aggregates, they do not address the intracellular accumulation of NFTs.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Biosplice Therapeutics, Inc., San Diego, CA, USA.

Background: DYRK1A overexpression, common in neurodegenerative diseases like Alzheimer's (AD), contributes to neurofibrillary tangles via Tau protein hyperphosphorylation and amyloid plaque formation, key AD hallmarks. Therefore, DYRK1A has been regarded as a novel target for neurodegenerative diseases. However, developing DYRK1A selective inhibitors has been a difficult challenge due to the highly conserved ATP-binding site of protein kinases, particularly among the CMGC family.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Yonsei University, Incheon, Incheon, Korea, Republic of (South).

Background: Cyclin Y (CCNY) is a member of cyclin protein family inhibiting long-term synaptic plasticity, which is related to the learning and memory function in neuronal system. Recently, CCNY has been reported to associate with the cognitive deficits in Alzheimer's disease (AD).

Method: In this study, we discovered PFTAIRE peptide to diminish CCNY protein level and to ameliorate cognitive dysfunction in AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!